Speaker Bio
Mark Driscoll, PhD
Chief Science Officer at Intus Inc.,
Dr. Driscoll has developed an innovative Next Gen Sequencing platform (“Titan-1”) that allows strain-level resolution, high-throughput, database-independent identification of the bacteria in a sample using a patented long read (16S-ITS-23S) amplicon followed by the use of proprietary AI and machine learning for discovery and insight. There are several research and clinical applications for this technology.